Literature DB >> 21575387

[Pathologic and molecular genetic study of anaplastic lymphoma kinase-positive large B-cell lymphoma].

Rong-fang Huang1, Gang CHEN, Li-ping GONG, Li-li LU.   

Abstract

OBJECTIVE: To study clinicopathologic and genetic features of anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma (LBCL).
METHODS: Light microscopy, EliVision immunohistocheimical method and fluorescence in-situ hybridization were used to evaluate three ALK + LBCL cases recently diagnosed accompanied with a literature review.
RESULTS: All three cases were male adult patients (mean age = 36.3 years) with nodal involvement by lymphoma. Histologic evaluation revealed a diffuse effacement of the nodal architecture by the infiltration of tumor cells. Sinusoidal infiltration was seen. The neoplastic cells were large and exhibited the immunoblastic/plasmablastic morphology. By immunohistochemistry, all the cases showed a cytoplasmic granular staining of ALK. They were positive for CD45, CD138, and epithelial membrane antigen (EMA), but were negative for CD3, CD20, CD79a and CD30. Fluorescence in situ hybridization (FISH) demonstrated the presence of ALK gene translocation in all of the cases.
CONCLUSIONS: ALK + LBCL represents a distinct variant of diffuse large B-cell lymphoma, usually involving lymph node of middle-aged men. The tumor has a immunoblastic/plasmablastic morphology along with a distinct immunophenotypic profile and ALK gene rearrangement.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21575387

Source DB:  PubMed          Journal:  Zhonghua Bing Li Xue Za Zhi        ISSN: 0529-5807


  1 in total

1.  Relapsed anaplastic lymphoma kinase-positive large B-cell lymphoma expressed cluster of differentiation 4 and cytokeratin: An initially misdiagnosed case corrected by immunoglobulin κ locus gene rearrangement detection.

Authors:  Yunfei Shi; Xianghong Li; Yuqin Song; Lixin Zhou; Qin Feng; Ping Wang; Chen Zhang; Weiping Liu; Yanhua Bai; Yumei Lai
Journal:  Oncol Lett       Date:  2017-05-17       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.